Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation

Kiran Reddy Kanubaddi, Shin-Han Yang, Li-Wei Wu, Chia-Hung Lee, Ching-Feng Weng Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan Abstract: Alzheimer’s disease (AD), an age-related neurodegenerative disease, the most c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kanubaddi KR, Yang SH, Wu LW, Lee CH, Weng CF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Alzheimer's disease amyloid beta bioavailability natural products nutraceutics Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8793435f0883481289ba14b33ad70302
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8793435f0883481289ba14b33ad70302
record_format	dspace
spelling	oai:doaj.org-article:8793435f0883481289ba14b33ad703022021-12-02T05:47:03ZNanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation1178-2013https://doaj.org/article/8793435f0883481289ba14b33ad703022018-12-01T00:00:00Zhttps://www.dovepress.com/nanoparticle-conjugated-nutraceuticals-exert-prospectively-palliative--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Kiran Reddy Kanubaddi, Shin-Han Yang, Li-Wei Wu, Chia-Hung Lee, Ching-Feng Weng Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan Abstract: Alzheimer’s disease (AD), an age-related neurodegenerative disease, the most common causes of dementia is a multifactorial pathology categorized by a complex etiology. Numerous nutraceuticals have been clinically evaluated, but some of the trials failed. However, natural compounds have some limitations due to their poor bioavailability, ineffective capability to cross the blood–brain barrier, or less therapeutic effects on AD. To overcome these disadvantages, nanoparticle-conjugated natural products could promote the bioavailability and enhance the therapeutic efficacy of AD when compared with a naked drug. This application generates and implements new prospect for drug discovery in neurodegenerative diseases. In this article, we confer AD pathology, review natural products in clinical trials, and ascertain the importance of nanomedicine coupled with natural compounds for AD. Keywords: Alzheimer’s disease, amyloid beta, bioavailability, natural products, nutraceuticalsKanubaddi KRYang SHWu LWLee CHWeng CFDove Medical PressarticleAlzheimer's diseaseamyloid betabioavailabilitynatural productsnutraceuticsMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 8473-8485 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Alzheimer's disease amyloid beta bioavailability natural products nutraceutics Medicine (General) R5-920
spellingShingle	Alzheimer's disease amyloid beta bioavailability natural products nutraceutics Medicine (General) R5-920 Kanubaddi KR Yang SH Wu LW Lee CH Weng CF Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
description	Kiran Reddy Kanubaddi, Shin-Han Yang, Li-Wei Wu, Chia-Hung Lee, Ching-Feng Weng Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien 97401, Taiwan Abstract: Alzheimer’s disease (AD), an age-related neurodegenerative disease, the most common causes of dementia is a multifactorial pathology categorized by a complex etiology. Numerous nutraceuticals have been clinically evaluated, but some of the trials failed. However, natural compounds have some limitations due to their poor bioavailability, ineffective capability to cross the blood–brain barrier, or less therapeutic effects on AD. To overcome these disadvantages, nanoparticle-conjugated natural products could promote the bioavailability and enhance the therapeutic efficacy of AD when compared with a naked drug. This application generates and implements new prospect for drug discovery in neurodegenerative diseases. In this article, we confer AD pathology, review natural products in clinical trials, and ascertain the importance of nanomedicine coupled with natural compounds for AD. Keywords: Alzheimer’s disease, amyloid beta, bioavailability, natural products, nutraceuticals
format	article
author	Kanubaddi KR Yang SH Wu LW Lee CH Weng CF
author_facet	Kanubaddi KR Yang SH Wu LW Lee CH Weng CF
author_sort	Kanubaddi KR
title	Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
title_short	Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
title_full	Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
title_fullStr	Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
title_full_unstemmed	Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
title_sort	nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/8793435f0883481289ba14b33ad70302
work_keys_str_mv	AT kanubaddikr nanoparticleconjugatednutraceuticalsexertprospectivelypalliativeofamyloidaggregation AT yangsh nanoparticleconjugatednutraceuticalsexertprospectivelypalliativeofamyloidaggregation AT wulw nanoparticleconjugatednutraceuticalsexertprospectivelypalliativeofamyloidaggregation AT leech nanoparticleconjugatednutraceuticalsexertprospectivelypalliativeofamyloidaggregation AT wengcf nanoparticleconjugatednutraceuticalsexertprospectivelypalliativeofamyloidaggregation
_version_	1718400241729798144

Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation

Ejemplares similares